---
layout: default
title: Acebutolol
description: "Acebutolol çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 2 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 11
evidence_level: L4
indication_count: 2
---

# Acebutolol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>2</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Acebutololï¼šå¾é«˜è¡€å£“å¿ƒå¾‹ä¸æ•´åˆ°æƒ¡æ€§è…è¡€ç®¡é«˜è¡€å£“

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Acebutolol å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Acebutolol åŸæœ¬ç”¨æ–¼é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡åŠå¿ƒå¾‹ä¸æ•´ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æƒ¡æ€§è…è¡€ç®¡é«˜è¡€å£“ (malignant renovascular hypertension)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **1 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ã€å¿ƒå¾‹ä¸æ•´ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | malignant hypertensive renal diseaseã€malignant renovascular hypertension |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.10% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 27 å¼µï¼ˆéƒ¨åˆ†å·²è¨»éŠ·ï¼‰ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. malignant hypertensive renal disease</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.10%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Acebutolol æ˜¯ä¸€ç¨®é¸æ“‡æ€§ beta-1 äº¤æ„Ÿç¥ç¶“é˜»æ–·åŠ‘ï¼Œå…·æœ‰å…§åœ¨æ“¬äº¤æ„Ÿæ´»æ€§ (ISA)ã€‚å…¶é™å£“æ©Ÿè½‰åŒ…æ‹¬æ¸›å°‘å¿ƒè¼¸å‡ºé‡ã€æŠ‘åˆ¶è…ç´ é‡‹æ”¾ï¼Œä»¥åŠä¸­æ¨æ€§é™å£“ä½œç”¨ã€‚

åœ¨è…è¡€ç®¡æ€§é«˜è¡€å£“çš„ç—…ç†æ©Ÿè½‰ä¸­ï¼Œè…ç´ -è¡€ç®¡å¼µåŠ›ç´ ç³»çµ± (RAS) éåº¦æ´»åŒ–æ‰®æ¼”é—œéµè§’è‰²ã€‚Beta é˜»æ–·åŠ‘èƒ½æŠ‘åˆ¶è…ç´ åˆ†æ³Œï¼Œç†è«–ä¸Šå¯èƒ½å°è…è¡€ç®¡æ€§é«˜è¡€å£“æœ‰è¼”åŠ©ç™‚æ•ˆã€‚1975 å¹´çš„æ³•åœ‹ç ”ç©¶ (PMID: 768911) æŒ‡å‡ºï¼Œacebutolol åœ¨è¡€æ¼¿è…ç´ æ´»æ€§å¢é«˜çš„è…è¡€ç®¡æ€§é«˜è¡€å£“æ‚£è€…ä¸­å±•ç¾è‰¯å¥½ç™‚æ•ˆã€‚

ç„¶è€Œï¼Œç›®å‰è‡¨åºŠä¸Šå°æ–¼æƒ¡æ€§è…è¡€ç®¡é«˜è¡€å£“çš„ä¸€ç·šæ²»ç™‚ä»ä»¥è¡€ç®¡ä»‹å…¥æˆ–æ‰‹è¡“ç‚ºä¸»ï¼Œè—¥ç‰©æ²»ç™‚å¤šä»¥ ACE æŠ‘åˆ¶åŠ‘æˆ– ARB ç‚ºé¦–é¸ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡é‡å° acebutolol èˆ‡æƒ¡æ€§è…è¡€ç®¡é«˜è¡€å£“çš„è¨»å†Šè‡¨åºŠè©¦é©—ã€‚

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [768911](https://pubmed.ncbi.nlm.nih.gov/768911/) | 1975 | Clinical Trial | La Nouvelle presse medicale | 50 ä¾‹é«˜è¡€å£“æ‚£è€…ä½¿ç”¨ acebutololï¼Œ74% æ•ˆæœè‰¯å¥½ï¼›ç ”ç©¶æŒ‡å‡ºè…è¡€ç®¡æ€§é«˜è¡€å£“ä¼´éš¨é«˜è…ç´ æ´»æ€§è€…ç‚ºè‰¯å¥½é©æ‡‰ç—‡ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. malignant renovascular hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.10%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.10%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026664è™Ÿ | é¹½é…¸é˜¿è¥¿å¸ƒç‰¹æ´› | ç²‰åŠ‘ | Beta äº¤æ„Ÿç¥ç¶“é®æ–·åŠ‘ |
| è¡›ç½²è—¥è£½å­—ç¬¬041669è™Ÿ | "ç”Ÿé”" èˆ’çˆ¾å¿ƒè†œè¡£éŒ  400mg | è†œè¡£éŒ  | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ã€å¿ƒå¾‹ä¸æ•´ |
| è¡›ç½²è—¥è£½å­—ç¬¬047472è™Ÿ | é †å¾‹è†œè¡£éŒ  400mg | è†œè¡£éŒ  | å¿ƒå¾‹ä¸æ•´ã€ç‹¹å¿ƒç—‡ã€é«˜è¡€å£“ |

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è—¥ç‰©äº¤äº’ä½œç”¨

**Major äº¤äº’ä½œç”¨ï¼š**
- Dolasetronï¼šå¯èƒ½å¢åŠ  QT å»¶é•·é¢¨éšª

**Moderate äº¤äº’ä½œç”¨ï¼š**
- é™è¡€ç³–è—¥ç‰©ï¼ˆGlimepirideã€Glipizideã€Glyburideã€å„é¡èƒ°å³¶ç´ ï¼‰ï¼šå¯èƒ½æ©è“‹ä½è¡€ç³–ç—‡ç‹€
- é¡å›ºé†‡ï¼ˆBetamethasoneã€Dexamethasoneã€Hydrocortisoneã€Prednisoloneã€Prednisoneï¼‰ï¼šå¯èƒ½æ¸›å¼±é™å£“æ•ˆæœ
- éˆ£é›¢å­è£œå……åŠ‘ï¼šå¯èƒ½å½±éŸ¿å¿ƒè‡Ÿå‚³å°
- è…ä¸Šè…ºç´ ï¼ˆEpinephrineï¼‰ï¼šå¯èƒ½ç”¢ç”Ÿåš´é‡é«˜è¡€å£“åæ‡‰
- Bupropionï¼šå¯èƒ½å¢åŠ é™å£“æ•ˆæœ
- Cimetidineï¼šå¯èƒ½å¢åŠ  acebutolol è¡€ä¸­æ¿ƒåº¦

**Minor äº¤äº’ä½œç”¨ï¼š**
- åˆ¶é…¸åŠ‘ï¼ˆAluminum hydroxideã€Magnesium hydroxideï¼‰ï¼šå¯èƒ½æ¸›å°‘å¸æ”¶
- Aspirinï¼šè¼•å¾®å½±éŸ¿é™å£“æ•ˆæœ

### ç¦å¿Œç—‡
- ç«‡æ€§å¿ƒæéç·©
- äºŒåº¦æˆ–ä¸‰åº¦æˆ¿å®¤å‚³å°é˜»æ»¯
- æ˜é¡¯å¿ƒè¡°ç«­
- å¿ƒå› æ€§ä¼‘å…‹

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šMany psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially duri...
- å»ºè­°ï¼šCaution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihype...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- Acebutolol should be used cautiously in patients with impaired hepatic function.

**Cerebrovascular Disorders** ğŸŸ¡ Moderate
- Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blo...

**é’å…‰çœ¼ (Glaucoma)** ğŸŸ¡ Moderate
- Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or disc...

**Hyperlipidemias** ğŸŸ¡ Moderate
- Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patient...

**ç”²ç‹€è…ºæ©Ÿèƒ½äº¢é€² (Hyperthyroidism)** ğŸŸ¡ Moderate
- When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid st...

*å¦æœ‰ 14 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
é›–ç„¶ acebutolol çš„è—¥ç†æ©Ÿè½‰ï¼ˆæŠ‘åˆ¶è…ç´ é‡‹æ”¾ï¼‰ç†è«–ä¸Šå¯èƒ½å°è…è¡€ç®¡æ€§é«˜è¡€å£“æœ‰ç›Šï¼Œä½†ç›®å‰åƒ…æœ‰ 1 ç¯‡ 1975 å¹´çš„æ–‡ç»æ”¯æŒï¼Œä¸”ç¾è¡Œè‡¨åºŠæŒ‡å¼•å°æ–¼æƒ¡æ€§è…è¡€ç®¡é«˜è¡€å£“å„ªå…ˆæ¨è–¦ä»‹å…¥æ²»ç™‚åŠ RAS é˜»æ–·åŠ‘ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- è¨­è¨ˆå‰ç»æ€§è‡¨åºŠè©¦é©—ï¼Œæ¯”è¼ƒ acebutolol èˆ‡æ¨™æº–æ²»ç™‚åœ¨è…è¡€ç®¡æ€§é«˜è¡€å£“çš„ç™‚æ•ˆ
- é€²è¡Œæ›´å¤šæ©Ÿè½‰ç ”ç©¶ï¼Œæ¢è¨ beta é˜»æ–·åŠ‘åœ¨é«˜è…ç´ ç‹€æ…‹ä¸‹çš„è§’è‰²
- èˆ‡è¡€ç®¡ä»‹å…¥æˆ–æ‰‹è¡“æ²»ç™‚çš„ä½µç”¨ç­–ç•¥ç ”ç©¶


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Cisatracurium]({{ "/drugs/cisatracurium/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Salicylamide]({{ "/drugs/salicylamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Dl-Alpha-Tocopherol]({{ "/drugs/dl-alpha-tocopherol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Brodalumab]({{ "/drugs/brodalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Hydroquinone]({{ "/drugs/hydroquinone/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Acebutololè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/acebutolol/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_acebutolol,
  title = {Acebutololè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/acebutolol/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
